retatrutide nejm 2023 obesity trial ly3437943 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a retatrutide phase 2 trial obesity

Intracellular sources of ornithine for polyamine synthesis in endothelial cells

Positive Phase 3 outcomes would be a prerequisite for any future regulatory submission to the MHRA for a marketing authorisation

It is typically preferred when a product is used over several weeks

Disclaimer: Reta Support and RetaTracker are for educational tracking and personal organization only

After reaction to horseradish peroxidase-conjugated secondary antibody (Bio-Rad, RRID:AB_11125547), the immunoreactive bands were developed with Immobilon Western Chemiluminescent HRP substrate (Millipore, Bedford, MA, USA) and were detected with LAS4000 imager (GE Healthcare, Piscataway, NJ, USA)

There can be no assurance that investment objectives will be met